Myriad RBM, Inc is a CLIA certified, multiplexed immunoassay testing laboratory that solves complex drug development challenges with innovative biomarker services. Myriad RBM’s internally developed and manufactured immunoassay kits based on Multi-Analyte Profiling (MAP) and ultrasensitive Single-Molecule Array (SimoaTM) technology, provide reproducible and quantitative data for hundreds of human proteins.
PreAnalytiX, a joint venture between BD and QIAGEN, develops, manufactures and sells integrated and standardized systems for sample collection, stabilization and purification of high-quality RNA, microRNA and DNA from human blood, bone marrow, or tissue specimens. The Company serves healthcare institutions, academic researchers, clinical laboratories and the pharmaceutical industry with a broad array of manual and automated products.
Oxford BioDynamics Plc is a biotechnology company focused on the discovery and development of epigenomic biomarkers for use within the pharmaceutical and biotechnology industries. The Company’s award-winning technology platform, EpiSwitch™, is designed to enable precision medicine programs by providing insights into disease mechanisms in early drug discovery, informing patient selection in clinical trials, and supporting product repositioning approaches. Oxford BioDynamics is headquartered in the UK and listed on the London Stock Exchange’s AIM under the ticker "OBD". For more information please visit www.oxfordbiodynamics.com.?
For nearly 20 years, Ambry has been seeking to better understanding gene-disease relationships through collaboration, research, and innovation. We have identified novel genes, designed custom assays, and brought to market more than 500 unique diagnostic tests. We’ve been first-to-market with game-changing technologies, including clinical exome and hereditary cancer panels. With our committed team of experts, we are equipped with powerful technologies and stand by ready to develop custom assays to meet your specific criteria.
Invivoscribe® is a comprehensive CDx partner, providing ISO13485 compliant biomarker development, cGMP manufacturing, regulatory capability, clinical trial services, and global commercialization. We offer internationally standardized testing through our ISO15189 laboratory network (US, Europe, Asia). Our Streamlined CDx™ approach has proven successful in approval of the first-ever AML companion diagnostic – The LeukoStrat® CDx FLT3 Mutation Assay, helping pharmaceutical companies accelerate FDA and PMDA approvals of new targeted therapies for the most deadly form of leukemia.
BioFluidica is a biotechnology company that has developed a diagnostic platform allowing for disease management and diagnosis through prognosis, all from a simple blood test. Biofluidica’s diagnostic platform can precisely capture and isolate disease biomarkers, such as Circulating Tumor Cells and has been clinically validated. Our ability to scan blood for the first signs of a disease means fulfilling the promise of a true liquid biopsy. We are revolutionizing disease diagnostics by improving diagnostics to millions of people.
Cureline, Inc is a global commercial biobank and human biospecimen CRO providing for 15 years effective solutions to biopharmaceutical and academic researchers. We maintain an extensive biorepository of human biospecimens in San Francisco Bay area. Our clinical network expands to over 16 countries and 100 clinical sites.
Viracor Eurofins BioPharma Services helps you advance clinical trials through trusted partnership, excellence in science and exceptional service. We customize assays to meet your study’s needs for phase I-IV trials, through our specialized testing and expertise in complex assay design/transfer, optimization and validation. Our CAP/CLIA and NY state accredited laboratory has over 30 years of experience in molecular testing, immune response monitoring, vaccine safety/efficacy assessment, allergy and hypersensitivity testing. For additional information, visit Viracor-Eurofins.com.
Singulex is an immunodiagnostics company at the forefront of Single Molecule Counting technology, a novel immunoassay technology recognized for unprecedented ultra sensitivity in the precision measurement of biomarkers. Singulex is the developer of the Singulex Clarity system, a fully automated, in vitro diagnostics platform powered by Single Molecule Counting technology. With up to 1000 times more sensitivity than existing technologies, Single Molecule Counting reveals the presence or absence of disease more clearly and definitively than was possible before. The Singulex Clarity system and Singulex Clarity assay received CE mark in 2017 and are commercially available in Europe; additional assays to detect and rule out infectious and inflammatory diseases are in development. Singulex is also developing a point-of-care platform and exploring applications beyond the clinical setting.
As an innovator in reagents and tools, Abcam’s purpose is to serve life science researchers globally to achieve their mission, faster. Providing the research and clinical communities with tools and scientific support, the Company offers highly validated biological binders and assays to address important targets in critical biological pathways.
Asuragen is a molecular diagnostic product company changing the way patients are treated in genetics and oncology. Asuragen’s diagnostic systems, composed of proprietary chemistry and software, deliver powerful answers using broadly installed instrument platforms. They are simple to adopt and expand the ability to serve patients. Asuragen is a product foundry rapidly and efficiently addressing current and emerging clinical needs, including cancer diagnosis and monitoring, reproductive health and aging, serving laboratories across a patient’s lifespan with its best in class diagnostic tests. Asuragen co-develops diagnostic tests with diagnostic and pharmaceutical partners on projects ranging from custom manufactured components to companion diagnostic tests.
Instant NanoBiosensors was founded in 2016 and based in Taiwan.
We focus on biomedical research and medical diagnostics and developed Fiber Optic Particle Plasmon Resonance (FO-PPR) technology, which offers simple, instant and accurate results for a wide range of detection applications.
Combining novel biomarkers with patented FO-PPR technology, our Point-Of-Care Testing (POCT) platform aspire to revolutionize traditional immunoassays because rapid and precise diagnostic make crucial differences by saving time, cost, and lives.